Skip to content
PLM Pundits
Report

Ayurveda Industry Outlook 2026: compliance, not demand, will pick the winners

Where Ayurveda is growing, why the revised Schedule T is the forcing event, and how a mid-size Indian manufacturer can turn compliance into credibility. A 12-page report by Prabandh.

Prabandh1 November 20262 min read

Download the report (PDF)

The argument in brief

Demand for Ayurveda is broad and durable. The report's view is that the 2026 rules, not demand, will decide who captures it: the revised Schedule T turns quality evidence from a cost into the price of staying in business.

What the report covers

  1. How big is it? Official AYUSH market estimates range from USD 23–24 bn to USD 43.4 bn depending on definition. The report reads the larger figure as a change of scope that adds services, and puts products and manufacturing at USD 20–25 bn.
  2. Where it is growing. Growth has moved from immunity products sold over the counter to nutraceuticals, standardised extracts and wellness services.
  3. Exports. India exports the ingredients while others build the brands. Finished medicines are a small share of AYUSH exports to the US, and product safety remains a credibility issue.
  4. A growth-attractiveness matrix for a mid-size maker: invest to lead in supplements, extracts and classical medicines; partner in services; be selective in personal care; harvest or reposition mass OTC and raw-herb exports.
  5. The forcing event. The Drugs (Eleventh Amendment) Rules, 2026 rewrite GMP for Ayurveda, Siddha and Unani units, with existing units required to comply by 31 July 2029. The report advises checking the Gazette notification before relying on the dates.
  6. The weak link. Wild-collected herbs, adulteration and price swings mean a batch cannot be proven without proving the herb.
  7. Seven moves, sequenced against the 2029 deadline, from closing the Schedule T gap and batch-wise heavy-metal testing to GACP-traced supply, export strategy and claims discipline.
  8. An illustrative case showing how Prabandh's Ayurveda edition maps to those moves. The demo company is fictional and the report says so.
  9. What to expect, honestly: vendor benchmarks labelled as such, and where Prabandh falls short today.

The common thread

One auditable record from field to invoice, batch by batch, that satisfies the inspector, the export buyer and the brand's auditor alike. Building that record is where diagnostics, process engineering and the right platform come together.

Related

Keep reading.

Perspective · FMCGDraft

Recipe to retail shelf: where FMCG margin leaks, and how to stop it

Food and snack brands rarely lose margin in the kitchen. They lose it in the gaps between recipe sheets, the plant, distributors and finance. Four leaks to look for, and why closing them starts with one data model.

25 October 2026 · 3 min read

Perspective · ShipbuildingDraft

Fix the thread before the tools

Most operations don't have a technology problem. They have a thread problem. Why disconnected product data, process and people undermine every new platform, and where to start instead.

22 October 2026 · 2 min read

Perspective · Discrete ManufacturingDraft

Where AI agents pay back first in manufacturing

The best first agent is rarely the most impressive demo. It is the high-volume, rules-heavy work your teams already do every day, wired into the systems they already use.

24 October 2026 · 2 min read

Start a conversation

Discuss this with a partner.

Tell us how this applies to your operations and a partner will come back with a working view of what to do first.

Request a consultationAll insights